ArticleBMC psychiatry2026
Development and validation of a model for predicting relapse in patients with first-episode schizophrenia.
Article in BMC psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe high relapse rate in schizophrenia leads to ongoing morbidity for patients and their families and places a substantial burden on both family systems and society. This study aimed to identify predictors associated with relapse and to develop and validate a nomogram model for estimating relapse risk in individuals with first-episode schizophrenia.
methodsA retrospective review of medical records was conducted on 426 patients with schizophrenia who were admitted for the first time between January 1, 2022, and December 31, 2023. A predictive model was developed based on the relapse status of patients within 1 year. Temporal validation was performed using an independent cohort of 182 patients with schizophrenia admitted from January to July 2024, serving as external validation data. Risk factors for 1-year relapse among individuals with first-episode schizophrenia were identified through Least Absolute Shrinkage and Selection Operator (LASSO) regression followed by multivariate logistic regression analyses. A nomogram model was then constructed to facilitate individualized prediction of relapse risk. Model performance was assessed using the area under the receiver operating characteristic (ROC) curve (AUC), calibration curves, and decision curve analysis (DCA).
resultsA nomogram model was developed by incorporating eight risk factors: onset form, co-residence, family type, place of residence, suicide risk, lack of interest/socialization, personal hygiene, and behavioral slowness. The model achieved an area under the curve (AUC) of 0.754 [95% confidence interval (CI) (0.707–0.802)] in the training set and 0.742 [95% CI (0.669–0.815)] in the external validation set. Calibration curves indicated good calibration, and DCA supported the clinical utility of the model.
conclusionThe model demonstrates moderate discriminatory power in predicting relapse within 1 year post-discharge for patients with first-episode schizophrenia. Given the accessibility of the predictive variables, clinicians can utilize this tool to predict and manage relapse in psychiatric patients. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.